Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.

Status:
Completed

Trial end date:
2017-10-01

Target enrollment:

Participant gender:

To characterize the pharmacokinetics and safety of alpelisib in subjects with hepatic impairment compared to matched healthy control subjects.

Phase 1

Novartis Pharmaceuticals